Status:
RECRUITING
ALA-induced Fluorescence Imaging of Breast Cancers Using the Handheld PRODIGI and Eagle Imaging Devices
Lead Sponsor:
University Health Network, Toronto
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
Breast cancer is the most commonly occurring cancer in women. Currently, breast conservation surgery (BCS) is the treatment most often prescribed. BCS involves removing the tumor while conserving the ...
Detailed Description
The investigators hypothesize that 5-ALA will selectively increase breast tumor-to-normal fluorescent contrast and therefore increase tumor margin delineation using the PRODIGI device compared to stan...
Eligibility Criteria
Inclusion
- Female patients with breast cancer
- 18 years or older
- Have consented for their standard surgeries for primary invasive breast cancers, with or without auxiliary procedure.
- Have existing biopsies banked at the hospital (for ALA patients)
Exclusion
- Pre-operative therapy (including chemotherapy, endocrine therapy and radiotherapy)
- Inability to consent
- Prior history of photosensitivity, liver disease, or recurrent disease
- Pregnancy
- Absence of in-house core biopsy in tissue bank
Key Trial Info
Start Date :
September 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2025
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT01837225
Start Date
September 1 2010
End Date
August 31 2025
Last Update
February 13 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G2M9
2
Princess Margaret Hospital
Toronto, Ontario, Canada, M5T 2M9